Buy tech sell-off, Wedbush’s Ives says: ’this is a 1996 moment, not 1999’
LONDON - Scancell Holdings plc (AIM:SCLP), a developer of cancer immunotherapies, announced Tuesday that Vulpes Testudo Fund has purchased 3,150,000 ordinary shares in the company. The fund is closely associated with Martin Diggle, who serves as a Non-Executive Director at Scancell.
The transaction took place on September 12, 2025, at a price of 8.861 pence per share, according to a company statement based on a regulatory filing.
Following this purchase, Vulpes Life Science Fund and Vulpes Testudo Fund together hold 143,537,037 ordinary shares, representing 13.83% of the company’s total shares.
Scancell, which trades on London’s AIM market, develops ImmunoBody and Moditope active immunotherapies for cancer treatment. The company’s lead product from its DNA ImmunoBody platform, iSCIB1+, is currently in Phase 2 trials for melanoma, while Modi-1 from its Moditope platform is being investigated in Phase 2 studies across various solid tumors.
The transaction was reported in accordance with regulatory requirements for disclosures of transactions by persons discharging managerial responsibilities and their closely associated persons.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.